CD8A and neoplasm: First, in the 4T1 breast tumor model, IL-15SA/IL-15RαSu-Fc was effective in reducing lung metastases, dependent on CD8+ T as well as NK cells, and increased the median overall survival from 38 to 50 days post–surgical resection of the primary tumor (Figure 7).